Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.

PharmTech recently spoke with Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs, to get his perspective on trends that shaped pharmaceutical development and manufacturing in 2025 and ...

According to API’s December 2025 announcements, the standards apply to CO2 transported in gaseous, liquid, and supercritical ...

For financial institutions, threat modeling must shift away from diagrams focused purely on code to a life cycle view ...

The Riverside closure underscores a hard truth: resilience is not free. Maintaining onshore or near-shore manufacturing ...

OpenX's new API suite provides ad buyers with a more detailed view of the bidstream and, as a result, more accurate targeting ...

Proposal aims to build a database of bulk drug traders, improve traceability of imported raw materials, over 70% of which ...

What is the best face swap video tool in 2026? The best choice depends on your workflow. Most teams choose based on realism, ...

Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the ...

Peptide therapeutics have progressed from insulin discovery to GLP-1 class molecules, revolutionizing diabetes treatment and ...

AI launches Grok Business & Enterprise AI plans with enterprise security, no data training, and higher limits.

As we bid 2025 goodbye, it’s only right to take one look back to wrap our heads around the year that was in all things AI.